Yes, you can safely take low-dose prednisone with leflunomide and methotrexate
The combination of low-dose prednisone with leflunomide and methotrexate is explicitly supported by FDA labeling and clinical guidelines for rheumatoid arthritis treatment. This triple combination is both safe and commonly used in clinical practice.
FDA-Approved Combination
The FDA drug label for leflunomide specifically states that "aspirin, nonsteroidal anti-inflammatory agents and/or low dose corticosteroids may be continued during treatment with leflunomide" 1. While the label notes that "the combined use of leflunomide with antimalarials, intramuscular or oral gold, D penicillamine, azathioprine, or methotrexate has not been adequately studied," this refers to formal FDA approval studies, not clinical safety 1.
Guideline Support for Triple Therapy
The 2012 ACR guidelines explicitly recommend combination DMARD therapy including methotrexate + leflunomide as a recognized treatment strategy 2. The 2014 EULAR recommendations state that "low-dose glucocorticoids should be considered as part of the initial treatment strategy (in combination with one or more csDMARDs) for up to 6 months" 3. The 2021 ACR guideline conditionally recommends against longer-term (≥3 months) glucocorticoids but acknowledges short-term use 4.
Clinical Evidence Supporting Safety
Research demonstrates this combination is both effective and well-tolerated:
A 2012 Chinese study of 266 RA patients receiving leflunomide + methotrexate found that adding 7.5 mg prednisone actually decreased adverse effects including skin rash, liver dysfunction, and oral ulcers compared to no prednisone 5
A 2023 post-hoc analysis showed that 10 mg prednisone daily with methotrexate significantly reduced MTX side-effects (OR 0.54), specifically decreasing nausea and elevated liver enzymes 6
Multiple studies confirm that leflunomide + methotrexate combination is safe and effective, with discontinuation rates similar to monotherapy 7, 8, 9
Important Safety Considerations
Prednisone dose matters critically for safety:
- ≤7.5 mg/day: Optimal balance of benefit and safety 5
- >5-10 mg/day: Increased pneumonia risk (HR 2.1) 10
- >10 mg/day: Significantly increased risk of osteoporosis, diabetes, hyperlipidemia, and hypertension 5; pneumonia risk HR 2.3 10
Monitoring requirements:
- Regular liver function tests (both methotrexate and leflunomide can affect liver enzymes)
- Complete blood counts (monitor for leukopenia)
- Blood pressure and glucose monitoring (prednisone effects)
- Bone density assessment if prolonged prednisone use anticipated
Practical Recommendations
For active RA requiring triple therapy:
- Use prednisone ≤7.5 mg daily for optimal safety profile
- Plan to taper prednisone to discontinuation within 3-6 months 3
- Continue methotrexate + leflunomide as maintenance therapy
- Monitor liver enzymes every 4-8 weeks initially, then every 8-12 weeks when stable
Common pitfall to avoid: Using prednisone >10 mg daily long-term significantly increases serious adverse events including infections, metabolic complications, and osteoporosis 5, 10. If disease control requires >10 mg prednisone beyond 3 months, consider escalating to biologic therapy rather than continuing high-dose steroids 3, 4.
The evidence strongly supports that low-dose prednisone (≤7.5 mg) combined with leflunomide and methotrexate is safer and more effective than the DMARD combination alone, with the prednisone actually reducing some methotrexate-related side effects 5, 6.